AJP - Heart Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol (November 18, 2005). doi:10.1152/ajpheart.00938.2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/5/H1826    most recent
00938.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hataishi, R.
Right arrow Articles by Ichinose, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hataishi, R.
Right arrow Articles by Ichinose, F.
Submitted on September 1, 2005
Accepted on November 11, 2005

Inhaled nitric oxide does not reduce systemic vascular resistance in mice

Ryuji Hataishi1, Warren M Zapol1, Kenneth D Bloch2, and Fumito Ichinose2*

1 Anesthesia and Critical Care, Massachusetts General Hospital, Boston, MA, USA
2 Anesthesia and Critical Care, Massachusetts General Hospital, Boston, MA, USA; Cardiovascular Research Center of the Department of Medicine, Massachusetts General Hospital, Charlestown, MA, USA

* To whom correspondence should be addressed. E-mail: fichinose{at}partners.org.

Inhaled nitric oxide (NO) is a highly-selective pulmonary vasodilator. It was recently reported that inhaled NO causes peripheral vasodilatation after treatment with a NO synthase (NOS) inhibitor. These findings suggested the possibility that inhibition of endogenous NOS uncovered the systemic vasodilating effect of NO or NO adducts absorbed via the lungs during NO inhalation. To learn whether inhaled NO reduces systemic vascular resistance in the absence of endothelial NOS, we studied the systemic vascular effects of NO breathing in wild-type mice treated without and with the NOS inhibitor N{omega}-nitro-L-arginine methyl ester (L-NAME) and in NOS3-deficient mice (NOS3-/-). During general anesthesia, the cardiac output, left ventricular function, and systemic vascular resistance were not altered by NO breathing at 80 parts per million (ppm) in both genotypes. Breathing NO in air did not alter blood pressure and heart rate, as measured by tail-cuff and telemetric methods, in either awake wild-type mice (whether or not they were treated with L-NAME), or in awake NOS3-/- mice. Our findings suggest that absorption of NO or NO adducts during NO breathing is insufficient to cause systemic vasodilation in mice even when endogenous NO production is congenitally absent.




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
K. D. Bloch, F. Ichinose, J. D. Roberts Jr., and W. M. Zapol
Inhaled NO as a therapeutic agent
Cardiovasc Res, July 15, 2007; 75(2): 339 - 348.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. T. Crossno Jr., C. V. Garat, J. E. B. Reusch, K. G. Morris, E. C. Dempsey, I. F. McMurtry, K. R. Stenmark, and D. J. Klemm
Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling
Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L885 - L897.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.